A c.464T>A mutation in VHL gene in a Chinese family with VHL syndrome

被引:0
作者
Yan Lu
Jun Lu
Qiang Liu
Jian Niu
Shi-Ming Zhang
Qing-Yu Wu
Xiao-Fei Qi
机构
[1] The First Affiliated Hospital of Soochow University,Department of Endocrinology
[2] People’s Hospital,Department of Neurosurgery
[3] The First Affiliated Hospital of Soochow University,Department of Gastroenterology
[4] Xuzhou Medical College Affiliated Hospital,Department of General Surgery
[5] The First Affiliated Hospital of Soochow University,Department of Neurosurgery
[6] Jiangsu Institute of Hematology,Department of Urology
[7] Cyrus Tang Hematology Center,undefined
[8] The First Affiliated Hospital of Soochow University,undefined
[9] The First Affiliated Hospital of Soochow University,undefined
来源
Journal of Neuro-Oncology | 2013年 / 111卷
关键词
Gene mutation; Hemangioblastoma; VHL syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Von Hippel–Lindau (VHL) is a tumor suppressor that negatively regulates the production of angiogenic factors. Mutations in the VHL gene cause VHL syndrome, which is characterized by highly vascularized tumors. Here we report a c.464T>A mutation of the VHL gene in three patients with hemangioblastoma from a Chinese family. This mutation was not reported previously and was absent in the unaffected family members. The mutation is predicted to cause Val to Glu substitution at VHL protein residue 155 in a conserved region. Previous biochemical studies demonstrated that residue Val-155 was critical for VHL protein binding to chaperonin TRiC/CCT, an essential step for proper VHL protein folding. Our finding of naturally occurring VHL V155E mutation in patients with VHL syndrome supports the functional importance of Val-155 residue in VHL protein and illustrates the diversity of VHL gene defects underlying VHL syndrome.
引用
收藏
页码:313 / 318
页数:5
相关论文
共 115 条
[1]  
Clifford SC(2001)Von Hippel–Lindau disease: clinical and molecular perspectives Adv Cancer Res 82 85-105
[2]  
Maher ER(2003)Von Hippel–Lindau disease Lancet 361 2059-2067
[3]  
Lonser RR(2002)Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2 673-682
[4]  
Glenn GM(2011)von Hippel–Lindau disease: a clinical and scientific review Eur J Hum Genet 19 617-623
[5]  
Walther M(2006)Von Hippel–Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment Jpn J Clin Oncol 36 337-343
[6]  
Chew EY(2007)VHL mutation analysis in patients with isolated central nervous system haemangioblastoma Brain 130 836-842
[7]  
Libutti SK(2012)Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy Nature 484 246-250
[8]  
Linehan WM(2008)Expression of Int J Mol Med 22 61-68
[9]  
Oldfield EH(2002) gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells J Med Genet 39 E38-496
[10]  
Kaelin WG(2011)Germline mutations in the von Hippel–Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire Neurol Sci 32 491-537